UB Paderborn / Katalog / Suche / in CDI

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

The Lancet (British edition), 2007-07, Vol.370 (9582), p.153-160

2007

Link zum Volltext

Verfügbarkeit prüfen

Effects of Torcetrapib in Patients at High Risk for Coronary Events

The New England journal of medicine, 2007-11, Vol.357 (21), p.2109-2122

2007

Link zum Volltext

Verfügbarkeit prüfen

Effect of Torcetrapib on the Progression of Coronary Atherosclerosis

The New England journal of medicine, 2007-03, Vol.356 (13), p.1304-1316

2007

Link zum Volltext

Verfügbarkeit prüfen

Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia

The New England journal of medicine, 2007-04, Vol.356 (16), p.1620-1630

2007

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL

Arteriosclerosis, thrombosis, and vascular biology, 2007-05, Vol.27 (5), p.1132

2007

Link zum Volltext

Verfügbarkeit prüfen

CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects

Arteriosclerosis, thrombosis, and vascular biology, 2014-09, Vol.34 (9), p.2106

2014

Link zum Volltext

Verfügbarkeit prüfen

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

The New England journal of medicine, 2017-04, Vol.376 (16), p.1517-1526

2017

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future

Pharmacological reviews, 2007-03, Vol.59 (1), p.40

2007

Link zum Volltext

Verfügbarkeit prüfen

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

Psychiatry research, 2001-04, Vol.101 (3), p.277-288

2001

Link zum Volltext

Verfügbarkeit prüfen

Relationship between atorvastatin dose and the harm caused by torcetrapib

Journal of lipid research, 2012-11, Vol.53 (11), p.2436-2442

2012

Link zum Volltext

Verfügbarkeit prüfen

Completeness of Carotid Intima Media Thickness Measurements Depends on Body Composition: The RADIANCE 1 and 2 trials

Journal of Atherosclerosis and Thrombosis, 2010, Vol.17(5), pp.526-535

2010

Link zum Volltext

Verfügbarkeit prüfen

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

Journal of the American Heart Association, 2015-08, Vol.4 (8), p.e002171-e002171

2015

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab

Journal of clinical lipidology, 2018-07, Vol.12 (4), p.958-965

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

Journal of the American College of Cardiology, 2006-11, Vol.48 (9), p.1782

2006

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels

Journal of the American College of Cardiology, 2006-11, Vol.48 (9), p.1774-1781

2006

Link zum Volltext

Verfügbarkeit prüfen

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2019-10, Vol.33 (5), p.571-579

2019

Link zum Volltext

Verfügbarkeit prüfen

Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia

Annals of medicine (Helsinki), 2010-09, Vol.42 (6), p.447-464

2010

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia

Arteriosclerosis, thrombosis, and vascular biology, 2008-01, Vol.28 (1), p.148

2008

Link zum Volltext

Verfügbarkeit prüfen

The failure of torcetrapib: is there a case for independent preclinical and clinical testing? - correspondence

Expert opinion on pharmacotherapy, 2008-10, Vol.9 (14), p.2561-2562

Shear, Charles L

2008

Link zum Volltext

Verfügbarkeit prüfen

Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis

Current medical research and opinion, 2007-04, Vol.23 (4), p.885-894

2007

Link zum Volltext

Verfügbarkeit prüfen

Torcetrapib and Atorvastatin

The New England journal of medicine, 2005-10, Vol.353 (14), p.1527-1529

Shear, Charles L

2005

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density LipoproteinCholesterolLevelsonaBackgroundofAtorvastatin

Journal of the American College of Cardiology, 2006-11, Vol.48 (9), p.1782-1790

2006

Link zum Volltext

Verfügbarkeit prüfen

Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up

The American journal of cardiology, 1994-10, Vol.74 (7), p.667-673

1994

Link zum Volltext

Verfügbarkeit prüfen

The failure of torcetrapib: is there a case for independent preclinical and clinical testing? - correspondence: Response to: Doggrell SA. The failure of torcetrapib: is there a case for independent preclinical and clinical testing? Expert Opin Pharmacother 2008;9(6):875-78

Expert opinion on pharmacotherapy, 2008-10, Vol.9 (14), p.2561-2562

Shear, Charles L

2008

Link zum Volltext

Verfügbarkeit prüfen

Value of childhood blood pressure measurements and family history in predicting future blood pressure status: results from 8 years of follow-up in the Bogalusa Heart Study

Pediatrics (Evanston), 1986-06, Vol.77 (6), p.862

1986

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

Effects of Torcetrapib in Patients at High Risk for Coronary Events

Effect of Torcetrapib on the Progression of Coronary Atherosclerosis

Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL

CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

Relationship between atorvastatin dose and the harm caused by torcetrapib

Completeness of Carotid Intima Media Thickness Measurements Depends on Body Composition: The RADIANCE 1 and 2 trials

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia

Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia

The failure of torcetrapib: is there a case for independent preclinical and clinical testing? - correspondence

Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis

Torcetrapib and Atorvastatin

Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density LipoproteinCholesterolLevelsonaBackgroundofAtorvastatin

Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up

The failure of torcetrapib: is there a case for independent preclinical and clinical testing? - correspondence: Response to: Doggrell SA. The failure of torcetrapib: is there a case for independent preclinical and clinical testing? Expert Opin Pharmacother 2008;9(6):875-78

Value of childhood blood pressure measurements and family history in predicting future blood pressure status: results from 8 years of follow-up in the Bogalusa Heart Study

Suchergebnisse filtern